Acquisition Opportunity Post-acquisition integration with TD2 broadens Flow Contract Site Laboratory’s reach into preclinical and clinical services, creating a sales opening to cross-sell GLP/non-GLP flow cytometry capabilities to TD2’s established client base.

Small Scale Advantage As a small CRO with a focused 8-color flow cytometry offering, target mid-market biotech companies and early-stage pharma sponsors seeking flexible, personalized CRO support and rapid turnaround for immunophenotyping and functional assays.

Service Expansion Capabilities in receptor occupancy, intracellular cytokine detection, phospho-protein analysis, and bead-based cytokine assays position FCSL to upsell integrated immune profiling packages to studies requiring comprehensive immuno-readouts.

Market Positioning Leverage niche expertise in processing diverse specimen types (whole blood, tissue, frozen PBMCs, tumors) to win projects in preclinical models and clinical trial work where flexibility and specialized sample handling matter.

Growth Levers Potential sales angles include partnering with TD2’s network, targeting clinical-stage programs needing nonclinical to clinical transition support, and offering scale-up options as client projects mature, despite current revenue under one million.